Second human trial of the Ad5-nCoV vaccine
The second human trial for Ad5-nCoV is being performed in Wuhan, China with primary outcomes in determining specific and neutralizing antibody responses and adverse reaction occurrences in subjects to determine the efficacy and safety of the vaccine. Another purpose of this trial was to further narrow down an appropriate dose for the vaccine candidate.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Learn After
Methods: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Results: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Discussion: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial